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Somatic mutations in the spliceosome gene ZRSR2 — located on the X chromosome — are 
associated with myelodysplastic syndrome (MDS). ZRSR2 is involved in the recognition of 3΄ 
splice site during the early stages of spliceosome assembly; however, its precise role in RNA 
splicing has remained unclear. Here, we characterize ZRSR2 as an essential component of the 
minor spliceosome (U12-dependent) assembly. shRNA mediated knockdown of ZRSR2 leads to 
impaired splicing of the U12-type introns, and RNA-Sequencing of MDS bone marrow reveals 
that loss of ZRSR2 activity causes increased mis-splicing. These splicing defects involve retention 
of the U12-type introns while splicing of the U2-type introns remain mostly unaffected. ZRSR2 
deficient cells also exhibit reduced proliferation potential and distinct alterations in myeloid and 
erythroid differentiation in vitro. These data identify a specific role for ZRSR2 in RNA splicing 
and highlight dysregulated splicing of U12-type introns as a characteristic feature of ZRSR2 
mutations in MDS.
Myelodysplastic syndromes (MDS) encompass a heterogeneous group of hematologic 
disorders collectively defined by aberrant differentiation of myeloid precursors in the bone 
marrow1,2. Because of the aging of our population, the incidence of the disease is increasing 
rapidly3. MDS is characterized by accumulation of abnormal myeloid precursors in the 
marrow which is accompanied by peripheral blood cytopenias. MDS often progresses to 
acute myeloid leukemia (AML), with a poorer prognosis compared to de novo AML4,5. 
Somatic mutations in several crucial genes including TET2, DNMT3A, RUNX1, ASXL1, and 
EZH2 have been implicated as causal genetic alterations in MDS6,7. More recently, second 
generation sequencing of MDS identified a high frequency of somatic mutations in the genes 
encoding for the RNA splicing machinery8. Recurrent mutations were detected by us and 
others in SF3B1, SRSF2, U2AF1, ZRSR2 and other spliceosome genes in independent 
cohorts of MDS, signifying a novel mechanism regulating the pathogenesis of this 
disease9–14. However, the functional consequence of these somatic mutations in the 
pathobiology of MDS remains largely unidentified.
RNA splicing is a fundamental process in eukaryotes which excises the intronic sequences 
from mRNA precursors to generate functional mRNA species. This function is carried out 
by the splicing machinery which comprises RNA-protein complexes called small nuclear 
ribonucleoprotein particles (snRNP). The major splicing machinery (termed U2 
spliceosome) involves 5 snRNPs (U1, U2, U4, U5 and U6) which function in concert with 
numerous other proteins to effect splicing of introns15. In addition, a second class of introns 
processed by a divergent spliceosome called minor (or U12) spliceosome was later 
identified16,17. The U12 machinery consists of U11, U12, U4atac, U6atac and U5 snRNPs 
and recognizes distinct intronic splice sites18–20. The U12-type introns coexist with U2-type 
introns in several genes involved in essential cellular functions such as DNA replication, 
RNA processing, DNA repair and translation21.
ZRSR2 (also known as URP) is located on X chromosome (Xp22.1) and encodes for a splice 
factor involved in recognition of 3’ intron splice sites. It interacts with other components of 
the pre-spliceosome assembly including the U2AF2/U2AF1 heterodimer and SRSF222. In 
vitro splicing assays suggest that ZRSR2 is required for efficient splicing of both the major 
and the minor class of introns23. In MDS, somatic mutations in ZRSR2 occur across the 
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entire length of the transcript, which is in contrast to mutational hotspots observed in SF3B1, 
SRSF2 and U2AF1. Moreover, nonsense, splice-site and frame-shift mutations in ZRSR2 
gene frequently occur in males, suggesting a loss of function. Mutations in ZRSR2 are more 
prevalent in MDS subtypes without ring sideroblasts and chronic myelomonocytic leukemia 
(CMML), and are associated with elevated percentage of bone marrow blasts and higher rate 
of progression to AML8,13. However, the mechanism linking ZRSR2 deficiency to 
pathogenesis of MDS has not been explored.
In this study, we have evaluated the cellular and functional consequences of the loss of 
ZRSR2 in cell lines and patient samples. We show that ZRSR2 plays a pivotal role in 
splicing of the U12-type introns while the U2-dependent splicing is largely unaffected. MDS 
bone marrow harboring inactivating mutations in ZRSR2 exhibit overt splicing defects, 
primarily involving the aberrant retention of U12-type introns. shRNA mediated knockdown 
of ZRSR2 similarly leads to impaired splicing of U12-type introns. Knockdown of ZRSR2 
also inhibits cell growth and alters the in vitro differentiation potential of hematopoietic 
cells. This study uncovers a specific function of ZRSR2 in RNA splicing and also suggests 
its role in hematopoietic development.
RESULTS
Knockdown of ZRSR2 leads to specific splicing defects
In MDS, somatic mutations in ZRSR2 are often inactivating alterations (nonsense, frame-
shift and splice site mutations) which primarily affect the males, signifying its loss-of-
function in these cases. To replicate the loss of ZRSR2, a lentiviral shRNA approach was 
used to stably downregulate its expression in human cells. Two shRNA vectors targeting 
ZRSR2 (ZRSR2 sh1 and sh2) were used to generate stable knockdown cells. These vectors 
resulted in efficient downregulation of ZRSR2 transcript and protein levels in 293T cells and 
leukemia cell lines, TF-1 and K562 (Fig. 1a,b and Supplementary Fig. 1).
Firstly, we examined the effect of ZRSR2 deficiency upon splicing, by transfection of 
minigene constructs in ZRSR2 knockdown and control transduced 293T cells. Two reporter 
constructs commonly used to assess splicing – P120 minigene24 and GH1 reporter 
plasmid25 – were used in these experiments. P120 minigene reporter consists of exons 5–8 
of human NOP2 (also known as NOL1 or P120) gene. We observed that the splicing of 
intron F, a U12-type intron, was reduced upon downregulation of ZRSR2 using both ZRSR2 
shRNA vectors (Fig. 1c,d). The GH1 minigene reporter consists of three exons and upon 
transfection, a fully spliced and exon skipped (missing the second exon) mRNA can be 
detected. Notably, in a previous study, ectopic expression of mutant U2AF1 - a splice factor 
related to ZRSR2 and also frequently mutated in MDS - results in higher frequency of exon 
skipping from GH1 minigene construct12. We observed that ZRSR2 knockdown and control 
293T cells exhibited comparable rates of exon skipping upon transfection of GH1 reporter 
construct (Supplementary Fig. 2). Therefore, our results highlight that ZRSR2 functions in a 
manner distinctive of U2AF1.
Next, we assessed splicing of endogenous introns in the MDS/AML cell line, TF-126, 
transduced with either ZRSR2 shRNA or control vector. ZRSR2 has been proposed to be 
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involved in splicing of both major and minor classes of introns23, therefore, splicing of both 
these types of introns was examined. All tested U12-dependent introns were less efficiently 
spliced in the ZRSR2 knockdown cells (Fig. 1e,f). The average ratio of spliced/unspliced 
RNA for the ten U12-type introns was 0.30 in sh1 transduced and 0.38 in sh2 transduced 
cells as compared to 1.0 in the control cells. Notably, the splicing of six U2-type introns was 
not significantly affected (spliced/unspliced ratio of 1.19 for sh1 and 0.96 for sh2 as 
compared to 1.0 for cells transduced with control shRNA) (Fig. 1e,f). Hence, the inability of 
ZRSR2 knockdown cells to splice efficiently endogenous and exogenous U12-type introns 
points towards a specific defect in the minor splicing machinery.
To test if overexpression of ZRSR2 can rescue the U12 splicing defects, we transiently 
transfected wild-type ZRSR2 into stably knockdown 293T cells (Supplementary Fig. 3a) 
and measured the splicing efficiency of U12-type introns. Ectopic expression of ZRSR2 
resulted in a significant increase in the splicing efficiency of all U12-type introns tested as 
compared to cells transfected with empty vector (Fig. 1g and Supplementary Fig. 3b). 
Therefore, we conclude that aberrant splicing observed in knockdown cells was a 
consequence of downregulation of ZRSR2. Overall, our experiments to evaluate splicing of 
endogenous and exogenous introns in ZRSR2 knockdown cells recognize its role in the U12 
spliceosome.
Inactivating ZRSR2 mutations in MDS cause splicing defects
To address the consequences of ZRSR2 mutations in MDS, a global evaluation of splicing 
alterations was performed using RNA Sequencing (RNA-Seq). RNA was extracted from 
bone marrow of eight male MDS patients harboring either nonsense or frame-shift mutations 
of ZRSR2 (Fig. 2a) (hereafter referred to as ‘ZRSR2 mutant MDS’). We also sequenced 
RNA from four MDS cases without mutation in either ZRSR2 or other commonly mutated 
splice factors (U2AF1, SF3B1 and SRSF2) (termed ‘ZRSR2 WT MDS’). In addition, three 
non-malignant bone marrows and one remission bone marrow (remission of sample #7; 
ZRSR2 mutant MDS) (Table 1) were also included as controls (termed ‘normal BM’). RNA-
Seq verified the presence of mutations in ZRSR2 with a high mutant allele frequency (range 
67.9%–98.0%) in all the ZRSR2 mutant MDS samples (Supplementary Fig. 4).
First, the RNA-Seq data were examined for abnormal sequencing reads at all splice 
junctions to assess the extent of mis-spliced events in different groups. The ‘normal’ reads 
comprised of those which aligned to the known exon-exon junctions, while ‘abnormal reads’ 
spanned exon-intron junctions or corresponded to splicing involving an ambiguous splice 
site as illustrated in Fig. 2b. We examined 298,275 unique splice junctions (23,786 RefSeq 
transcripts in 15,737 genes) for aberrant splicing, and each ZRSR2 mutant MDS sample was 
compared to a control sample (ZRSR2 WT MDS or normal BM) as described in the Methods 
section. Using a false discovery rate (FDR) cutoff of 0.01 and difference in Mis-splicing 
Index (ΔMSI)>20, significantly higher number of abnormally spliced junctions were 
detected in ZRSR2 mutant MDS samples compared to the ZRSR2 WT MDS samples in a 
majority of pairwise comparisons (Fig. 2c). Similarly, the number of such abnormal 
junctions was also elevated in ZRSR2 mutant group when compared to four normal BM 
samples (Fig. 2d). These findings suggested a higher incidence of aberrant splicing in 
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samples with ZRSR2 mutation as compared to controls. Notably, 689 mis-spliced junctions 
were identified in all eight ZRSR2 mutant MDS cases, signifying a subset of introns which 
represent bona-fide downstream targets of ZRSR2.
ZRSR2 mutant MDS is characterized by aberrant intron retention
To delineate the splicing defects that occur in ZRSR2 mutated cells, we carefully evaluated 
the RNA-Seq data of mutant and control bone marrows for aberrant intron retention, cryptic 
splice site usage and exon skipping. For identification of aberrant retention, introns with 
≥95% coverage and with sequencing reads supporting both 5’ and 3’ exon-intron junctions 
were considered (described in Methods section). We compared the proportion of aberrant 
reads (spanning across both exon-intron junctions) in each sample to calculate the Mis-
splicing Index (MSI) (Supplementary Fig. 5). The difference in the MSI values between the 
mutant and control samples (termed ΔMSI) was used as a measure of aberrant retention for 
each intron. Using this approach, we tested 110,192 introns, and performed pairwise 
analyses between eight ZRSR2 mutant MDS samples and eight controls (four ZRSR2 WT 
MDS and four normal BM samples) to obtain 64 sets of comparisons. We observed that 
elevated number of retained introns was clearly evident in ZRSR2 mutant MDS as compared 
to either ZRSR2 WT MDS or normal BM samples (Fig. 3a,b). Importantly, significant intron 
retention was not detected when comparing the ZRSR2 WT MDS to normal BM samples 
(Fig. 3c), underlining that the intron retention is specific to mutations in the ZRSR2 gene.
We further examined the retained introns in ZRSR2 mutated cases for the type of intron. The 
introns were categorized as either U2- or U12-type based on the divergence at the 5’ and 3’ 
splice sites and the branchpoint sequence20,21, utilizing the computational method described 
previously27. This analysis revealed a striking overabundance of U12-type introns amongst 
the aberrantly retained introns in ZRSR2 mutant MDS samples (Fig. 3a,b,d,e). This pattern 
was observed consistently across all the pairwise comparisons between ZRSR2 mutant and 
control samples (Fig. 3d,e), while the comparisons between ZRSR2 WT MDS and normal 
BM (16 pairwise comparisons) did not show any intron type-specific retention (Fig. 3f). 
Next, to ascertain the subset of introns which were consistently retained in ZRSR2 mutant 
samples (ΔMSI>20), we focused on introns recognized in a large number of pairwise 
comparisons. Expectedly, the number of retained introns identified in successively 
increasing numbers of pairwise comparisons gradually decreased (Supplementary Fig. 6), 
however, the proportion of U12-type introns among the retained introns steadily climbed 
(Fig. 3g). In fact, 43 out of 45 introns retained in the ZRSR2 mutant MDS in all 64 
comparisons were U12-dependent. On the other hand, specific intron retention in the ZRSR2 
WT and normal BM groups (ΔMSI<-20) was not apparent, and no intron was retained in 
more than 41 pairwise comparisons (Fig. 3g). Consequently, amongst the high-ranking set of 
introns consistently retained (present in >41 pairwise comparisons) in the ZRSR2 mutant 
MDS, a disproportionately higher prevalence (85%) of U12-type introns occurred (Fig. 3h 
and Supplementary Data 1), thereby, underscoring the involvement of ZRSR2 in the minor 
spliceosome machinery. Moreover, among the retained U2-type introns, 72% were 
contained in a transcript also harboring a U12-type intron, with the retained U2-type intron 
typically located immediately downstream of the U12-type intron (Fig. 3h and 
Supplementary Fig. 7). This indicates that the inefficient splicing of U12-type introns can 
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also cause mis-splicing of neighboring U2-type introns within the transcript. Only 11 U2-
type introns which were independent of U12 transcripts were identified as aberrantly 
retained in our computational approach (Supplementary Data 1). These introns were 
indistinguishable from other unaffected U2-type introns (data not shown) and invariably 
displayed a weaker retention phenotype compared to the U12-type introns.
Though our preceding analysis identified that the U12-type introns were significantly 
retained in ZRSR2 mutant MDS, we further inquired whether the splicing of all U12-type 
was affected. To address this, we examined the aberrant retention of each U12-type intron 
using the average ΔMSI values for mutant vs control groups. Of all the genes harboring 
U12-type introns in the human genome27, 28, genes containing 558 U12-introns were 
expressed at sufficient levels (FKPMmax>1; FKPMaverage>0.5). Firstly, ΔMSI calculations 
showed that practically all U12-type introns were mis-spliced, albeit to varying extent, in the 
ZRSR2 mutant MDS group (Supplementary Fig. 8). This is also evident in individual 
pairwise comparisons between ZRSR2 mutant MDS and control samples (Fig. 3d,e). Next, 
we classified the U12-type introns based on the ΔMSI values and found that the splicing of 
only 29 introns (ΔMSI≤0) (5% of expressed U12-type introns) was unaffected 
(Supplementary Data 2). Although, we did not detect any difference in the distribution of 
GT-AG vs AT-AC intron type with the retention phenotype, the U12-type introns which are 
not retained in ZRSR2 mutant cells tend to be longer (median length 1,958 nucleotides 
compared to 1,039 for significantly retained introns) (Supplementary Data 2). Interestingly, 
the unaffected GT-AG introns had relatively weaker splice sites as indicated by lower 5’ 
splice site score compared to the retained introns (Supplementary Data 2).
We also sequenced mRNA from TF-1 cells in which ZRSR2 was downregulated using 
either sh1 or sh2 lentiviral vectors. Stable knockdown cells from two independent 
transduction experiments were used to examine for intron retention as described above. 
Expression analysis confirmed 60–70% reduction in ZRSR2 transcript levels in the 
knockdown cells (Fig. 3i). The suppression of ZRSR2 in these knockdown cells resulted in 
marked retention of U12-type introns as compared to control shRNA transduced cells (Fig. 
3j,k). Overall the number of retained introns obtained in knockdown TF-1 cells was lower 
than those identified in ZRSR2 mutant MDS cases. This is conceivable because of low levels 
of ZRSR2 present in the knockdown cells as compared to complete absence in males with 
either nonsense or frame-shift mutations. Importantly, amongst the retained introns 
identified in both sh1 and sh2 knockdown cells, a large proportion were U12-type introns 
(Fig. 3l). Notably, we observed a sizable overlap of U12-type introns retained in both ZRSR2 
mutant MDS and knockdown TF1 cells (Supplementary Fig. 9).
Next, to validate the aberrant intron retention, quantitative RT-PCR (qRT-PCR) was used to 
measure the normalized intronic expression in ZRSR2 mutant MDS and control samples. 
Using this approach, we tested eight representative U12-type introns detected as aberrantly 
retained in our computational analysis. We observed markedly higher expression of all 
tested introns in each of the mutant samples as compared to the control samples (Fig. 4a–h). 
In a parallel analysis, we also detected higher expression of these introns in ZRSR2 
knockdown TF1 cells (Supplementary Fig. 10) signifying consistent findings in our two 
experimental models.
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The experimental evidence of U12-type intron retention specifically in ZRSR2 deficient 
MDS samples further substantiates ZRSR2 as a crucial component of the U12-dependent 
spliceosome.
Additional mis-splicing events in ZRSR2 mutant MDS
Further, using an approach similar to the one to detect intron retention, we searched for mis-
splicing events involving abnormal recognition of 5’ and 3’ splice sites (Supplementary Fig. 
5). We identified several loci where cryptic splice sites were observed in ZRSR2 mutant 
MDS. We focused on loci which displayed aberrant splicing in all mutant cases and found 
that the majority of them were associated with transcripts containing U12-type introns. 
These events usually occurred either within the U12-type introns or in its vicinity. The 
incorrect recognition of splice sites resulted in a varied pattern of mis-splicing involving 
ambiguous splice donor and acceptor sites which invariably generated cryptic U2 splice 
junctions (Fig. 5). As representative examples of abnormal splice site recognition in ZRSR2 
mutant MDS, mis-spliced U12-type introns in WDR41, FRA10AC1 and SRPK2 genes were 
experimentally validated.
The intron 4 of human WDR41 gene is a U12-type intron. RNA-Seq revealed a distinctive 
pattern of mis-splicing in all ZRSR2 mutant samples which includes retention of the 5’ 
portion of intron followed by multiple mis-splicing events employing cryptic U2-type splice 
sites within the intron 4 (Fig. 5a,b and Supplementary Data 3,4). We verified presence of 
such aberrant splice junctions across exons 4 and 5 involving the two cryptic exons (4A and 
4B) using qRT-PCR. The levels of mis-spliced products were substantially higher in the 
ZRSR2 mutant MDS as compared to either the ZRSR2 WT MDS or normal BM samples 
(Fig. 5c,e). Moreover, Sanger sequencing of the products amplified from ZRSR2 mutant 
samples verified the predicted splice junctions (Fig. 5d,f). We detected two alternative splice 
donor sites (4’ and 4” located 19 bp apart) both of which resulted in splicing to cryptic exon 
4A (Fig. 5g,h). Similarly, in FRA10AC1 and SRPK2, anomalous splice junctions were 
created from cryptic U2-type splice sites which resulted in partial retention of U12-type 
introns in ZRSR2 mutant samples (Fig. 5i,j, Supplementary Fig. 11a,b and Supplementary 
Data 3,4). The presence of these alternative splicing junctions was also validated by PCR 
and Sanger sequencing (Fig. 5k,l and Supplementary Fig. 11c,d). Likewise, in conventional 
RT-PCR analysis of WDR41, FRA10AC1 and SRPK2, aberrantly spliced transcripts were 
detectible only in ZRSR2 mutant MDS samples (Supplementary Fig. 12).
We also detected a few instances of increased exon skipping in the ZRSR2 mutant group. 
The exon skipping was observed in the transcripts containing the U12-type introns and often 
involved exons flanking the U12-type intron (Supplementary Data 5).
Downregulation of ZRSR2 alters growth and differentiation
We investigated the consequences of ZRSR2 suppression upon cell growth and 
hematopoietic differentiation using shRNA mediated knockdown. We observed that the 
ZRSR2 deficient leukemia cells divided moderately slower than the cells transduced with 
control shRNA vector (data not shown). In soft agar colony assay, downregulation of 
ZRSR2 resulted in pronounced reduction in the number of colonies obtained in TF-1 and 
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K562 cells (Fig. 6a). In Propidium Iodide staining of steady state TF-1 cells, fewer cells 
were detected in S-phase of the cell cycle (Supplementary Fig. 13a). Also, lower proportion 
of ZRSR2 knockdown cells incorporated BrdU in in vitro labeling assay (Supplementary 
Fig. 13b), indicating that ZRSR2 deficient cells divide slower than the control cells. We 
further tested the in vivo tumorigenic potential of ZRSR2 knockdown K562 cells in mice. 
Cells were injected subcutaneously in NSG mice, and the tumor growth was assessed. 
ZRSR2 deficient K562 cells produced smaller tumors as compared to the cells transduced 
with control shRNA (Fig. 6b). These results illustrate that downregulation of ZRSR2 
suppresses cellular growth both in vitro and in vivo.
Next, the implications of ZRSR2 deficiency on myeloid differentiation were investigated 
using an in vitro model of differentiation of human CD34+ hematopoietic stem cells 
(HSCs). CD34+ cells enriched from cord blood were transduced with either ZRSR2 shRNA 
or control shRNA lentivirus and analyzed for in vitro clonogenic growth in methylcellulose 
media. We observed a marked decrease in the number of BFU-E colonies obtained after 9 
days. On the other hand, a notable increase in CFU-M colonies occurred while the number 
of CFU-G colonies was unaffected (Fig. 6c). We confirmed an effective knockdown of 
ZRSR2 in transduced cells using qRT-PCR (Supplementary Fig. 14). Next, we evaluated the 
differentiation profile of CD34+ cells using flow cytometry. Following transduction with 
lentivirus, cells were cultured in the presence of cytokines for 2 weeks. A significant 
increase in the proportion of CD11b+ myeloid cells was observed in cultures upon 
knockdown of ZRSR2 (Fig. 6d,e). Downregulation of ZRSR2 also resulted in a reduced 
proportion of erythroid precursors co-expressing Glycophorin A and CD71 surface antigens 
(Fig. 6f,g). These results indicate that suppression of ZRSR2 alters erythroid and myeloid 
differentiation of HSCs, presumably as a result of dysregulated splicing of genes implicated 
in hematopoiesis.
Pathways regulated by mis-spliced genes in ZRSR2 mutant MDS
To reveal the enrichment of functionally related genes among the significantly mis-spliced 
transcripts in ZRSR2 mutant MDS (Supplementary Data 1,4,5), Gene Ontology (GO) 
analyses was performed using the standard enrichment computation method. A significant 
enrichment was obtained for several pathways (p<0.05) including mitogen-activated protein 
kinase (MAPK) signaling, ErbB signaling and for genes associated with chronic myeloid 
leukemia and acute myeloid leukemia (Fig. 7a). We sought to identify downstream targets of 
aberrant splicing of ZRSR2 which may contribute to the disease phenotypes. Several genes 
which participate in either hematopoietic differentiation or are implicated in myeloid 
malignancies were consistently mis-spliced in all ZRSR2 mutant MDS samples (Fig. 7b). 
For instance, members of E2F transcription factors - E2F1, E2F2, E2F3, E2F4 and E2F6 - 
which function during myeloid differentiation29–35 exhibit splicing defects in ZRSR2 mutant 
cells. Similarly, various regulators of MAP kinase signaling, including MAPK1, MAPK3, 
RAS guanyl releasing proteins and RAF serine/threonine protein kinases contain U12-type 
introns and were mis-spliced in ZRSR2 mutant cells. These proteins mediate vital signaling 
cascades and their role in maintaining physiological hematopoiesis has been identified36–44. 
Another interesting candidate is the tumor suppressor gene, PTEN, loss of which impairs 
HSC activity, alters their lineage commitment and leads to myeloid disorders in mice45,46. 
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Dysregulation of these genes through aberrant splicing can potentially have direct 
implications upon hematopoietic differentiation and may contribute to the pathogenesis of 
MDS. Further investigations are necessary to identify effector(s) of the MDS phenotype in 
ZRSR2 mutant cells.
Overall, our results demonstrate that ZRSR2 mutations lead to aberrant splicing, primarily 
involving U12-type introns. These splicing defects are also corroborated in knockdown cells 
which display alterations in growth and differentiation, substantiating an essential and non-
redundant role of ZRSR2 in the U12-dependent spliceosome.
DISCUSSION
Discovery of mutations in several spliceosome genes in MDS strongly suggest existence of 
dysfunctional splicing machinery in this disease. Interestingly, majority of the mutated genes 
including SF3B1, U2AF1, ZRSR2, SRSF2, SF1 and SF3A18, encode for components of E/A 
splicing complex which is involved in the recognition of splice sites. Recurrent somatic 
mutations in these genes which occur mutually exclusively indicate that the disruption of 
initial splicing steps is a common feature in MDS. Therefore, these mutations can be 
predicted to cause widespread alterations in splicing and gene expression. However, 
contrary to this hypothesis, mutations in U2AF1 and SF3B1 exert splicing changes in a 
specific subset of introns and exons11,47,48. Hence, this raises the question whether each 
splice factor mutations has a distinctive effect on the splicing machinery which possibly 
results in diverse phenotypes. In fact, evidence shows an association between splice factor 
mutation and the clinical phenotype. SF3B1 mutations are found at high frequency in MDS 
subtypes characterized by presence of ring sideroblasts, SRSF2 mutations are highly 
associated with CMML, while mutations in ZRSR2 are often observed in RAEB-1 and 
RAEB-2 subtypes8,13,47,49–52 In this study, we demonstrate that the depletion of ZRSR2 
leads to a specific splicing defect by disrupting the splicing of the entire subset of U12-type 
introns. Therefore, our study and previous reports indicate that the mutations in individual 
splice factors are likely to alter the function of splicing machinery in an exclusive manner.
Our results define an essential role of ZRSR2 in splicing of U12-type introns and propose it 
as one of the key components of the minor spliceosome. Our lentiviral shRNA mediated 
knockdown approach demonstrates a specific defect in splicing of U12-type introns which 
can be reversed by transient overexpression of ZRSR2. Most notably, RNA-Seq revealed 
that the transcriptome of ZRSR2 mutant MDS exhibited several splicing defects, invariably 
resulting from inefficient splicing of U12-type introns. Surprisingly, the U2-type introns 
were spliced with similar efficiency as the control cells. Although ZRSR2 has been shown to 
be also required for in vitro splicing of U2-type introns22,23, our results provide the first 
evidence that in vivo splicing of U2-type introns is essentially unaffected in the absence of 
ZRSR2. We detect significant retention of U2-type introns only in transcripts which contain 
U12-type introns. Rare U2-type introns independent of U12 transcripts appear in our 
analysis of mis-spliced introns. However, these introns exhibit weak mis-splicing phenotype 
and do not indicate any specificity with respect to either splice site strength or intron length, 
and therefore, are likely outliers in our analysis. These results signify ZRSR2 is crucial to 
U12 spliceosome machinery while it may have either a limited or redundant role in the U2 
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machinery. Additionally, ZRSR2 has been identified as a component of U11/U12 snRNP53 
and also a crucial role of ZRSR2 in U12-dependent spliceosome was also noted by the 
inability of cell extract lacking ZRSR2 to form a U12 splicing complex assembly in in vitro 
assays23. Further, a perfect correlation exists in the phylogenetic distribution of organisms 
that have both ZRSR2 and U12-dependent splicing, which also strongly supports the 
involvement of this splice factor in the U12 machinery23. Our computational analysis also 
demonstrates that ZRSR2 mutations cause mis-splicing of a majority of U12-type introns, 
except for a minor subset with weaker U12-type splice sites.
ZRSR2 contacts the 3’ splice site of the U12-type intron of P120 transcript by binding the A 
residue of the AC dinucleotide at the 3’ splice site23. This suggests that ZRSR2 is needed for 
recognition of 3’ splice sites in U12-type introns. Interestingly, the U12-spliceosome 
complexes (Complex A and Complex B/C) failed to assemble at P120 pre-mRNA in its 
absence23, indicating that recognition of the whole intron is impaired. Analysis of our RNA-
Seq data also suggests that the ZRSR2 mediated 3’ splice site recognition is required for the 
5’ splice site and branch site recognition. This is evident by activation of cryptic 5’ splice 
site sequences in certain U12-type intron containing transcripts like DRAM2, TAPT1, 
VPRBP etc. in ZRSR2 mutant MDS (Supplementary Fig. 15). Similar instances of cryptic 
splice sites were previously reported for deficiency of RNPC3 and U11–48K, proteins also 
involved in the U12 splicing machinery54,55. The cryptic splice junctions observed in ZRSR2 
mutant cells were invariably U2-type.
Unlike the U2-dependent spliceosome, the U12-dependent machinery has been less well 
understood and proteins involved in splice site recognition are not clearly defined. U12 
spliceosome was initially uncovered as a machinery instrumental in excising introns lacking 
the consensus GT-AG splice site termini56. However, it was soon recognized that this 
splicing complex was responsible for a unique subset of evolutionary conserved introns 
which had a highly conserved splice site recognition sequences distinct from the U2-type 
introns16,17,21,24 and which utilized different snRNPs than those used in U2 machinery18,19. 
Although the U12-type introns comprise ~ 0.5% of all human introns, they exist in several 
crucial genes involved in vital cellular processes57. Germline mutations in the RNU4ATAC 
gene, which encodes for an essential component of the U12 spliceosome, have been shown 
to cause MOPD1/TALS (Microcephalic Osteodysplastic Primordial Dwarfism type 1 / 
Taybi-Linder Syndrome), a rare developmental disorder in humans58,59. Biallelic mutations 
in RNPC3 gene which encodes for a 65 kDa constituent of U11/U12 di-snRNP also lead to 
isolated familial growth hormone deficiency55. Moreover, an intact U12 spliceosome is 
essential for the development of Drosophila (despite the presence of <20 U12-type introns in 
its genome) and zebra fish60–62. Thus, the questions raised in the context of myeloid 
neoplasms are: what are the consequences of the impairment of U12 splicing specifically in 
hematopoietic stem cells and how the ZRSR2 mutations (and other spliceosome gene 
mutations, in general) contribute to leukemogenesis. We show that knockdown of ZRSR2 in 
human HSCs alters their in vitro differentiation potential. Reduced differentiation occurs 
towards erythroid lineage accompanied by a higher proportion of CD11b+ myeloid cells 
upon knockdown of ZRSR2. These results suggest that a competent U12 spliceosome is 
required for normal myeloid differentiation. Further investigations will focus on identifying 
Madan et al. Page 10
Nat Commun. Author manuscript; available in PMC 2015 July 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
downstream target genes, which upon mis-splicing lead to pathogenic consequences in 
MDS. In this study, the GO analysis of U12-type genes identifies few such molecular 
pathways with potential involvement in the MDS phenotype. We find that genes encoding 
E2F transcription factors and several components of the Ras/Raf/MEK/ERK signaling 
exhibit aberrant splicing of U12-type introns consistently in all ZRSR2 mutant MDS. These 
proteins have been implicated in normal and malignant hematopoiesis and represent possible 
candidates for future investigations. Studies using murine models will help identify 
downstream targets and better understand the role of ZRSR2 mediated splicing in 
hematopoietic differentiation. Pathway analysis of mis-spliced genes also revealed a strong 
enrichment of key cellular functions such as RNA transport, cell cycle, cellular response to 
stress, response to DNA damage stimulus, protein transport, protein serine/threonine kinase 
activity and ribonucleotide binding among the mis-spliced genes (Supplementary Fig.16). 
These functional classes have been previously attributed to the genes containing the U12-
type introns57.
Downregulation of ZRSR2 impaired in vitro clonogenic ability and suppressed tumor 
formation in mice. Overall, the ZRSR2 knockdown leukemia cells showed a general 
tendency to grow slower than the control cells. This observation is similar to the effect on 
cell growth reported for other spliceosome mutations. Expression of mutant U2AF1 
suppressed the growth of cell lines and resulted in lower reconstitution potential in mice8. 
Cell cycle arrest and inhibition of growth in leukemia cell lines is also attributed to 
downregulation of SF3B163. Therefore, the spliceosome mutations do not seem to contribute 
towards a proliferative advantage of the hematopoietic precursors in MDS. How these cells 
harboring spliceosome mutations achieve clonal expansion remains unclear. One 
explanation can be that other accompanying genetic alterations are necessary to confer a 
proliferative advantage. In fact, mutations in several components of epigenetic machinery 
co-occur with spliceosome mutations. A high incidence of co-occurrence of mutations in the 
TET2 and ZRSR2 genes has been noted in MDS8,13. Loss of TET2 has been shown to lead to 
myeloproliferation and transformation of hematopoietic precursors in mice64,65. Therefore, 
mutations in TET2 are likely to promote clonal dominance. Mutations in spliceosome genes, 
which occur early during leukemogenesis66, might play a prominent role in modifying the 
differentiation potential of myeloid precursors, thus contributing to abnormal precursor 
phenotype, which is a hallmark of MDS. Further studies into co-operativity between 
mutations in spliceosome and epigenetic modifier genes in pathogenesis of myeloid 
disorders are therefore warranted.
METHODS
Generation of stable ZRSR2 knockdown cell lines
Lentiviral shRNA vectors (pLKO.1) were either purchased from Sigma or assembled by 
cloning the shRNA hairpin loop sequence into the AgeI/EcoRI sites of the empty vector. 
The target sequence for the ZRSR2 shRNAs sh1 and sh2 are 5’-
CAACAGTTCCTAGACTTCTAT-3’ and 5’-AGCAGCCCTTTCTCTGTTTAA-3’, 
respectively. MISSION pLKO.1-puro Non-Mammalian shRNA Control (SHC002; Sigma) 
was used as control vector for transduction. To generate lentiviral particles, 293T cells 
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(kindly provided by Dr. Bing Lim, Genome Institute of Singapore, Singapore) were co-
transfected with shRNA plasmid and the packaging plasmids, pMISSIONgagpol and 
pMISSIONvsvg (Sigma) using Lipofectamine 2000 (Invitrogen). Virus containing 
supernatant was collected after 48 and 72 hours, filtered through 0.45 μm filter and stored in 
aliquots at −80°C. TF-1 and K562 cells (American Type Culture Collection) were infected 
with lentivirus for 2 rounds, 24 hours apart, in the presence of 5 μg/ml protamine sulfate. 
Transduced cells were selected in puromycin to generate stable knockdown cell lines. The 
knockdown was verified using qPCR and western blotting.
Western blot analysis
Total protein lysates were prepared using M-PER Mammalian Protein Extraction Reagent 
(Thermo Scientific) containing protease inhibitor cocktail (Roche). 25 μg protein was 
resolved on 10% SDS-PAGE gel and transferred to Immobilon-P PVDF membrane 
(Millipore). Anti-ZRSR2 antibody (1:2500 dilution) (kindly provided by Dr Michael Green, 
University of Massachusetts Medical School, Massachusetts) was used to determine ZRSR2 
protein expression. The membrane was stripped before probing with anti-GAPDH antibody 
(1:5000 dilution) (Cell Signaling Technology).
Minigene splicing assays
P120 reporter construct was generously provided by Dr Richard A. Padgett, Cleveland 
Clinic, Cleveland, Ohio and the GH1 minigene plasmid was provided by Dr Kinji Ohno, 
Center for Neurological Diseases and Cancer, Nagoya, Japan. 293T cells were transfected 
with P120 or GH1 plasmids using jetPRIME transfection reagent (Polyplus Transfection 
SA). Briefly, cells in 60mm dish were transfected with 200 ng of reporter plasmid. Cells 
were harvested 48h after transfection, and total RNA was extracted using AxyPrep 
Multisource Total RNA Miniprep Kit (Axygen). RNA was treated with DNase I followed by 
cDNA synthesis using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific). For 
P120 minigene assay, plasmid specific primer was used for reverse transcription. The cDNA 
was used as a template to amplify the region of P120 gene containing intron F at 94°C for 2 
min followed by 25 cycles of 94°C for 30 sec, 60°C for 40 sec, 72°C for 40 sec and a final 
extension at 72°C for 7 min. Amplified PCR product was resolved on agarose gel, stained 
with ethidium bromide and photographed. Bands corresponding to spliced (112 bp) and 
unspliced (211 bp) products were quantified using Image Lab software (Biorad).
For GH1 minigene, reverse transcription was performed using random primers. The PCR to 
amplify the GH1 transcript was performed at 94°C for 2 min followed by 28 cycles of 94°C 
for 30 sec, 60°C for 40 sec, 72°C for 40 sec and a final extension at 72°C for 7 min. 
Amplicons corresponding to fully spliced and exon skipped transcripts measured 447 bp and 
327 bp, respectively. The sequences of primers used for RT-PCR are provided in the 
Supplementary Table 1.
RT-PCR to determine splicing efficiency of U2-type and U12-type introns
Splicing of U2-type and U12-type introns was measured using qRT-PCR47,59. Briefly, RNA 
was treated with DNase I (Thermo Scientific) followed by reverse transcription using 
RevertAid M-MuLV Reverse Transcriptase (RevertAid First Strand cDNA Synthesis Kit; 
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Thermo Scientific) in the presence of random primers. Spliced and unspliced levels of 
introns were measured using two separate qPCRs and normalized to GAPDH transcript 
levels. PCR conditions included an initial denaturation at 95°C followed by 40–50 cycles of 
denaturation at 95°C for 15 sec and annealing/extension at 60°C for 30 sec. Primer 
sequences used for U2-type and U12-type introns are provided in Supplementary Table 1. 
Splicing efficiency was calculated as a ratio of relative quantities of spliced and unspliced 
pre-mRNA levels and was set as 1 for the control transduced cells.
Overexpression of ZRSR2
Full length coding sequence of human ZRSR2 gene (1449 bp) was amplified using PCR and 
cloned into BamHI/NotI sites of pCDNA3.1 expression vector (Invitrogen). 2 μg plasmid 
was used to transfect 293T cells in a 60 mm petri dish using jetPRIME transfection reagent 
(Polyplus Transfection) according to the manufacturer’s protocol. RNA was extracted 72 
hours after transfection and overexpression of ZRSR2 was verified using qPCR. RTPCR to 
assess the splicing efficiency of U12-type introns was performed as described above.
Bone marrow samples
Bone marrow aspirates of diagnostic samples including MDS and non-malignant cases were 
obtained at the MLL Munich Leukemia Laboratory. Informed consent was obtained in 
accordance with the Declaration of Helsinki and approved by the Institutional Review Board 
of the MLL. Unfractionated bone marrow mononuclear cells were lyzed, and total RNA was 
extracted using RNeasy Kit (Qiagen).
Soft-agar colony assay
Colony forming ability of TF-1 and K562 cells was determined by plating the cells in semi-
solid media containing agar. The bottom layer consisted of 0.5% agar supplemented with 
20% FBS, RPMI-1640 medium and antibiotics/antimycotic (Gibco). 1500 cells were mixed 
with the top agar layer which contained 0.35% agar and RPMI-1640 medium, FBS, L-
Glutamine, β-mercaptoethanol and antibiotics/antimycotic, which was plated in each well of 
24-well dish. 2 weeks after plating, colonies were enumerated under the microscope from 
triplicate wells.
Xenograft tumor model
All mice experiments were approved by the Institutional Animal Care and Use Committee, 
National University of Singapore, Singapore. Ten million K562 cells were resuspended in 
50% matrigel and injected subcutaneously into flank of eight weeks old female NOD-scid-
gamma (NSG) mice. Each mouse was injected with control cells in one flank and the 
ZRSR2 knockdown cells in the other. Once tumors were palpable, mice were sacrificed, 
tumors were harvested and weighed.
In vitro differentiation of human CD34+ cells
CD34+ cells were enriched from fresh cord blood and transduced twice, 24 hours apart, with 
ZRSR2 shRNA lentivirus. For colony assay, 2,500 transduced cells were plated per well in a 
6-well dish in methylcellulose media (Stemcell Technologies) supplemented with SCF, G-
Madan et al. Page 13
Nat Commun. Author manuscript; available in PMC 2015 July 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
CSF, GM-CSF, IL-3 and EPO and containing puromycin. Colonies were enumerated after 9 
days. In some experiments, cells were harvested from colonies and used to extract RNA. 
Downregulation of ZRSR2 was examined using qRT-PCR. For liquid culture, cells were 
maintained in the presence of SCF, GM-CSF, IL-3, EPO and puromycin for 2 weeks. 
Expression of Glycophorin A and CD71 (erythroid lineage) and CD11b (myeloid lineage) 
was determined using flow cytometry. Data were analyzed using Flowjo software.
RNA sequencing
Library preparation, sequencing and mapping—cDNA libraries were prepared 
using TruSeq RNA Sample Preparation Kit (Illumina) according to the manufacturer’s 
protocol. 1 μg of total RNA was used for library preparation and paired end adapters were 
ligated to DNA fragments prior to amplification and sequencing on a HiSeq 2000 instrument 
(Illumina) with 100 bp paired end reads according to manufacturer's protocol. We first 
mapped the sequenced reads to the reference transcript in the database obtained from 
RefSeq, Ensemble and UCSC known genes using bowtie and unmapped or poorly mapped 
reads were realigned to human reference genome (hg19) with the Blat software. This two-
step mapping procedure is included in genomon-fusion (http://genomon.hgc.jp/rna/) 
pipeline.
The mapped reads were organized into five different libraries a) exon read library, 2) intron 
read library, 3) exon-intron junction read library, 4) exon-exon junction read library, and 5) 
intergenic read library. The gene classification was done using all known RefSeq transcripts. 
In order to be considered as a real junction, two criteria were applied. Firstly, we required 
the splice junction to be supported by at least 5 reads, and aligned reads spanned a minimal 
of 4 bp on each side of the junction.
Differential splicing analysis—In order to identify splicing events, we introduced a 
parameter called Mis-splicing Index (MSI), which is equivalent to Percent Spliced in (PSI) 
values used for alternative splicing analysis67,68 and modified to cater to different splicing 
events such as intron retention, exon skip, and incorrect splice site usage (see Supplementary 
Fig. 5 for mathematical expression of MSI). For identification of differential splicing 
between two samples, the difference in MSI (ΔMSI) was applied: ΔMSI = MSIZRSR2 mutant 
– MSIcontrol. Furthermore, we used the Fisher’s exact test to evaluate the significance of 
such difference and adjusted p value by FDR analysis to minimize the false positives. For 
identification of differentially spliced events among two genotypes, we performed all 
possible pairwise analyses between ZRSR2 mutant MDS and control (ZRSR2 WT MDS and 
normal BM) samples. These include 32 comparisons each between ‘ZRSR2 mutant MDS’ 
and ‘ZRSR2 WT MDS’ or ‘ZRSR2 mutant MDS’ and ‘normal BM’ (total 64 pairwise 
comparisons). As control, ZRSR2 WT MDS samples were compared to normal BM samples 
(4 × 4 = 16 comparisons). Similar approach was used to compare the rate of mis-splicing in 
ZRSR2 knockdown vs control transduced TF-1 cells. Statistical difference of p≤0.01 and 
difference in Mis-splicing Index (ΔMSI) of >20 were considered as significant differential 
splicing in each comparison. To identify an overall significant mis-splicing between the two 
genotypes (ZRSR2 mutant vs controls), we considered the frequency of occurrence of mis-
splicing events in pairwise comparisons and applied a FDR of ≤0.01 for intron retention and 
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≤0.02 for abnormal splice site recognition and exon skip analysis, using the control-vs-
control comparisons as background.
For intron retention analysis, we selected events where at least 1 read overlaps an intron and 
flanking exons at each of the two junctions and the total number of such junction read 
counts was a minimum of 4, in at least one sample. We also applied the criteria that ≥95% of 
the intron was covered by at least 1 read (Supplementary Fig. 17).
Classification of introns—First, position weight matrices were generated based on the 
5’ and 3’ splice sites and the branch site sequence. These matrices were used to scan the 
introns of interest, and the introns were then categorized as U2-type or U12-type based on 
the mapping score27.
Gene expression analysis—The relative abundance of transcripts was quantified using 
normalized fragments per kilobase of transcript per million fragments mapped (FPKM), 
which were calculated using bedtools with a transcriptome reference.
Gene function analysis for mis-spliced genes—Genes significantly mis-spliced in 
ZRSR2 mutant MDS cases were analyzed using Gene Ontology (GO) tools to identify 
enriched GO terms for biological pathways, biological processes and molecular functions. 
Significant enrichment was computed based on the Fishers’ exact test using the numbers of 
mis-spliced genes compared to the numbers in the genome for each GO term. The obtained 
P value was further corrected for false discovery rate as described69. GO pathway analysis 
tool used was the MetaCore from GeneGO (https://portal.genego.com/) and the GO analysis 
for biological processes and molecular functions was done with DAVID (http://
david.abcc.ncifcrf.gov). The corrected P value cutoff of 0.05 was used for significant 
enriched GO terms. Heat maps were created for enriched biological processes and molecular 
functions using Cluster 3.0 software.
Validation of mis-spliced genes—Intron retention in ZRSR2 mutant MDS was verified 
using qRT-PCR70. Expression of each intron was normalized against the expression of 
flanking exons. For validation of other mis-spliced introns, qPCR or conventional PCR were 
used. GAPDH was used as the normalization control for cDNA input. Primer sequences are 
available in the Supplementary Table 1.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Knockdown of ZRSR2 induces defects in splicing of U12-type introns
(a) Transcript levels of ZRSR2 in TF-1 cells stably transduced with either lentiviral ZRSR2 
shRNA or control (con) vectors were examined using quantitative RT-PCR. GAPDH levels 
served as endogenous control. (b) Western blot analysis to verify the decrease in ZRSR2 
protein levels in knockdown TF-1 cells. (c) Splicing efficiency of Intron F of P120 minigene 
construct was measured in ZRSR2 knockdown and control 293T cells. A representative gel 
picture shows bands corresponding to unspliced and spliced product in RT-PCR analysis 
performed 48h after transfection of minigene plasmid. (d) The bars depict ratio of intensities 
of PCR bands corresponding to spliced and unspliced products in P120 minigene assay. The 
data represent the mean ± SEM of three independent transfection experiments. *P < 0.05, 
**P <0.01; Unpaired t test. (e and f) Average ratio of spliced to unspliced pre-mRNA levels 
of ten U12-type and six U2-type introns in TF-1 cells upon knockdown of ZRSR2 using two 
shRNA vectors, ZRSR2 sh1 (e) and ZRSR2 sh2 (f). The data are mean ± SEM from at least 
3 independent RNA preparations. Horizontal dotted lines represent the ratio for control 
transduced cells which were set as 1.0. GAPDH was used as endogenous control. (g) 
Average ratios of spliced to unspliced levels of U12-type introns upon transient transfection 
of ZRSR2 expression plasmid in knockdown 293T cells are depicted. 293T cells stably 
expressing ZRSR2 sh1 or control vector were transfected with either pCDNA3-hZRSR2 or 
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empty vector and total RNA was extracted after 72h. The splicing efficiency was measured 
using qPCR and spliced/unspliced ratio was set as 1.0 for control cells transfected with 
empty vector (horizontal dotted line). GAPDH was used to normalize for cDNA input. The 
results are average of 5–7 transfection experiments and represented as mean ± SEM.
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Figure 2. RNA sequencing of MDS bone marrow harboring mutations in ZRSR2 reveals splicing 
defects
(a) Schematic representation of human ZRSR2 protein with position and type of mutations 
in eight MDS patients used for RNA-Seq. (b) Approach used to define the RNA-Seq reads 
for analysis of splice junctions is shown. All splice junctions corresponding to known 
RefSeq transcripts were examined. Reads mapped to a representative splice position 
(Junction 1) are classified as either ‘normal’ or ‘aberrant’ in the illustration. (c) Number of 
junction positions with aberrant reads obtained in pairwise comparisons between ZRSR2 
mutant and WT MDS are depicted. Junctions with significant aberrant reads in ZRSR2 
mutant (ΔMSI>20) are shown as red bars while those in ZRSR2 WT (ΔMSI<-20) are shown 
as blue bars for each mutant vs WT pair. The dashed horizontal lines denote the averages of 
aberrant junction positions in the two genotypes across 32 comparison pairs (eight ZRSR2 
mutant MDS compared individually to four ZRSR2 WT MDS). (d) Number of aberrant 
junctions obtained in pairwise comparisons between ZRSR2 mutant MDS and normal BM 
analyzed and depicted as described in (c). The black bars represent number of aberrant 
junctions detected in normal BM. The green bars in (c) and (d) represent the number of 
junctions which were identified in all eight mutant / eight control samples in at least one 
pairwise comparison. Each pair of bars in (c) and (d) is labelled with identifiers for ZRSR2 
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mutant and control samples represented in their pair-wise comparison. The sample 
information including details of ZRSR2 mutations are described in Table 1.
Madan et al. Page 23
Nat Commun. Author manuscript; available in PMC 2015 July 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. ZRSR2 mutated MDS bone marrow and ZRSR2 knockdown cells are characterized by 
aberrant retention of U12-type introns
(a–c) Dot plots display aberrantly retained introns in a representative pairwise analysis of 
ZRSR2 mutant MDS vs ZRSR2 WT MDS (a), ZRSR2 mutant MDS vs normal BM (b) and 
normal BM vs ZRSR2 WT MDS (c). Each dot denotes an intron and U12-type introns are 
shown in red. p value was calculated using Fisher’s exact test and data points with p<0.01 
are shown. (d–f) Histograms depict frequencies of U2-type and U12-type introns plotted 
against ΔMSI value in pairwise comparisons of ZRSR2 mutant and control samples. Each 
curve represents a pairwise comparison for U2-type (blue) and U12-type (red) intron. 32 
comparisons between ZRSR2 mutant MDS and ZRSR2 WT MDS (d), 32 comparisons 
between ZRSR2 mutant MDS and normal BM (e), and 16 comparisons between ZRSR2 WT 
MDS and normal BM (f) were performed. (g) The proportion of U2-type and U12-type 
introns among aberrantly retained introns in either ZRSR2 mutant or controls (ZRSR2 WT 
MDS + normal BM) are shown for 64 pairwise comparisons. The number of introns is 
plotted against the number of pairwise comparisons in which they were identified. (h) 
Distribution of intron type for significantly retained introns (ΔMSI>20; FDR≤0.01) in 
ZRSR2 mutant MDS is shown. The bar graph shows the distribution of retained U2-type 
introns into those present in either transcript containing a U12-type intron or without U12-
type intron. (i) Relative expression of ZRSR2 was computed as FPKM values from RNA-
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Seq data in two independently transduced control and knockdown TF-1 cells. (j–k) Dot 
plots depict aberrantly retained introns in control vs ZRSR2 sh1 (j) and control vs ZRSR2 
sh2 (k). Only data points corresponding to p<0.01 are displayed. (l) Venn diagram shows an 
overlap of retained introns between ZRSR2 sh1 and sh2 knockdown TF-1 cells. The introns 
which are significantly retained (p<0.01; ΔMSI>10) for sh1 or sh2 transduced cells in both 
experiments are included. The bar graph on the right depicts the proportion of U2-type and 
U12-type introns among the introns retained in both sh1 and sh2 transduced cells.
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Figure 4. Detection of U12-type intron retention in ZRSR2 mutant MDS
(a–h) Normalized intron expression for eight representative U12-type introns was 
determined using quantitative PCR. The RNA-Seq reads normalized to total number of 
mappable reads for all 16 cases are depicted using IGV 2.3 in the left panels. Read counts 
are shown using an identical scale in all samples, and the U12-type introns are indicated by 
orange arrow heads. For each gene, only the genomic locus containing the retained intron is 
shown. Right panels: The expression of U12-type introns was measured relative to the 
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expression of flanking exons and is shown by horizontal bars (red bars: ZRSR2 mutant 
MDS; blue bars: ZRSR2 WT MDS; black bars: normal BM).
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Figure 5. Cryptic splice junctions in U12-type introns of WDR41 and FRA10AC1
(a) Normalized RNA-Seq reads mapped to the genomic region encompassing exons 4 and 5 
of WDR41 gene are displayed using IGV 2.3 for all 16 samples. Reads in all samples are 
shown on identical scale. (b) Aberrant splice junctions in intron 4 (U12-type intron) of 
WDR41 gene are depicted. The mis-spliced regions (designated 4A and 4B) and two 
alternative splice donor sites in intron 4 (upstream of 4A; marked as 4’ and 4”) in ZRSR2 
mutant samples are illustrated. The intron type and length for the cryptic junctions are 
indicated. The cryptic splice acceptor and donor sequences which are activated in ZRSR2 
mutant MDS are shown below. The PCR primers used in (c) and (e) are indicated by arrows. 
(c–d) Experimental verification of splicing junction between 4B and exon 5 of WDR41. (c) 
qRT-PCR using primers located in 4B and exon 5 to determine relative levels of mis-spliced 
transcript in ZRSR2 mutant and control samples. (d) The PCR product amplified from 
cDNA of ZRSR2 mutant samples in (c) was Sanger sequenced. The junction is shown by 
dashed vertical line. (e–f) Splicing between 4A and 4B was analyzed as described above in 
(c) and (d), respectively. (g–h) Sanger sequencing of the PCR amplicon obtained from 
cDNA of ZRSR2 mutant samples using primers located in 4A and retained intron (upstream 
of 4’). The PCR product was cloned into TOPO TA vector and individual clones were 
sequenced to verify two alternative splice donor sites (4’ and 4”). (i) RNA-Seq reads 
mapped to the genomic region encompassing exons 3–6 of FRA10AC1 gene. (j) Aberrant 
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splice donor site (denoted 4’) in intron 4 of FRA10AC1 is shown for a representative ZRSR2 
mutant sample. Sequence and intron-type for the cryptic splice junction are indicated. (k) 
qRT-PCR to measure the relative levels of mis-spliced RNA in ZRSR2 mutant and control 
samples using primers located in intron 4 and exon 5. GAPDH was used to normalize the 
levels of transcripts. (l) Sanger sequencing of the PCR product obtained from ZRSR2 mutant 
samples in (j). The junction between intron 4 and exon 5 is indicated by the dashed vertical 
line.
Madan et al. Page 29
Nat Commun. Author manuscript; available in PMC 2015 July 14.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. Stable knockdown of ZRSR2 alters cell growth and differentiation
(a) Colony forming ability of TF-1 and K562 cells transduced with ZRSR2 shRNA and 
control vectors was evaluated using soft-agar colony assay. 1500 cells were seeded in each 
well of a 24-well plate, and colonies were enumerated after 2 weeks. Cells were plated in 
triplicate, and the data are the mean ± SEM from multiple experiments (TF-1: n=8 for sh1 
and n=3 for sh2; K562: n=2) (b) ZRSR2 knockdown and control K562 cells were 
transplanted into the flank of NSG mice; tumors were dissected after 2 weeks and weighed. 
Data represent mean ± SEM. (c) Cord blood derived CD34+ cells were transduced with 
ZRSR2 shRNA lentivirus and plated in methylcellulose media containing SCF, IL3, GCSF, 
GMCSF and EPO as well as 1 μg/ml puromycin. BFU-E, CFU-G and CFU-M colonies were 
counted after 9 days. Data represent the mean ± SEM of three experiments. (d–g) CD34+ 
cells were transduced as in (c), cultured in liquid media containing SCF, IL3, GMCSF and 
EPO for 2 weeks and analyzed using flow cytometry. (d) A representative overlay of 
histograms showing staining with CD11b antibody used as a marker of differentiation 
towards myeloid lineage. (e) Percentage of CD11b+ cells obtained after in vitro 
differentiation of CD34+ cells in 4 experiments are depicted (mean ± SEM). (f) Erythroid 
differentiation was measured using surface expression of Glycophorin A and CD71 antigens 
in cells cultured for 2 weeks in the presence of cytokines. Representative dot plots for FACS 
staining in ZRSR2 knockdown and control cells are shown. Percentage of cells in each 
quadrant are indicated. (g) Bar graphs represent percentages of GlyA+CD71+ cells from 3 
experiments (mean ± SEM). *P<0.05, **P<0.01. P values were calculated using Student’s t 
test.
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Figure 7. Gene Ontology (GO) analyses of mis-spliced genes in ZRSR2 mutant MDS
(a) GO analysis of 251 significantly mis-spliced genes in ZRSR2 mutant MDS shows their 
enrichment in a number of essential biological pathways (p<0.05). (b) Heat map portrays the 
relative scale of aberrant retention of U12-type introns in genes involved in hematopoietic 
development. MSI values for U12-type introns in ZRSR2 mutant and control samples were 
utilized for depiction of mis-splicing.
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